Treatment therefore contrasts the loss of cell-cell dependent adhesion underpinning melanoma development and progression, and indicating the opportunity for targeted clinical intervention similarly to what has been observed in the so-called ‘actin-diseases’, i.e. those with a disruption of the E-cadherin and actin connection [52]. The gene discussed is CDH1; the disease is glycogen storage disease VI.